ASCO: Merck bills Keytruda, used around surgery, as new standard in 'messy' early lung cancer realm
Fierce Pharma
JUNE 1, 2023
As doctors weigh various immunotherapy strategies for the treatment of early-stage non-small cell lung cancer, Merck & Co. | As doctors navigate the "messy" early-stage non-small cell lung cancer landscape with various immunotherapy approaches, Merck & Co. has now unveiled new data that it hopes can establish Keytruda, used before and after surgery, as a new standard of care.
Let's personalize your content